Policy

Policy

Beijing Draws a Line: What China's Proposed Biopharma Export Ban Means for the Global Deal Machine

China's proposed ban on foreign acquisitions of advanced biotech platforms marks a significant shift in how Beijing views its biotech sector, though out-licensing deals remain unaffected.

Policy

China Draws a Line Around Its Biotech Crown Jewels

China's new technology export restrictions aim to prevent foreign acquisition of key biotech platforms while permitting licensing arrangements, marking a shift toward more managed cross-border biotech dealmaking.

Policy

Rewriting the Rules: What the FDA's Rare Disease Framework Initiative Means for Drug Development

The FDA's new Rare Disease Framework Initiative proposes to make fit-for-purpose evidentiary standards the default for rare disease drug development. Here is what it means and why it matters.

Policy

The Price of Principle: What PhRMA's GLOBE Lawsuit Reveals About the Future of Drug Pricing in America

PhRMA's lawsuit against the Trump administration's GLOBE drug pricing model reveals deeper industry anxieties about international price benchmarking becoming a normalized tool of American drug policy.

Biotechnology

Light as Medicine: What the Nobel Prize for Optogenetics Means for the Future of Brain Therapies

The 2026 Nobel Prize in Medicine went to the pioneers of optogenetics. With the first optogenetic therapy approaching FDA approval and psychiatric applications in clinical trials, the prize marks a turning point for neuroscience drug development.

Pharmaceuticals

Thirty Years in the Making: What Kerendia's Approval Means for Type 1 Diabetes and Kidney Disease

The FDA's approval of Kerendia for type 1 diabetes-associated kidney disease marks the first new treatment option in over 30 years for this underserved patient population.

Policy

Racing China to the Starting Line: What the FDA's New IND Pilot Really Means for Drug Development

The FDA launched its Expedited IND Pilot Program on September 15, 2026, as part of Operation TrialBlazer. The ambition is real, but the delays driving research offshore run deeper than the mechanism being deployed to address them.

Biotechnology

The Long Road to a First: What uniQure's Huntington's Disease Gene Therapy Filing Really Means

uniQure has filed the first-ever gene therapy application for Huntington's disease. The science is compelling, the regulatory backstory is dramatic, and the stakes for 30,000 Americans and 200,000 at-risk individuals could not be higher.

Biotechnology

Medicine Made to Order: What ARPA-H's $125 Million RNA Manufacturing Bet Really Means

ARPA-H's $125 million GIVE program aims to revolutionize RNA medicine manufacturing through distributed, automated platforms that can produce personalized therapies on demand near patients.

Biotechnology

When the Promise Meets the Risk: What the Novartis and BMS Autoimmune CAR-T Halts Really Mean

Novartis and Bristol Myers Squibb paused their autoimmune CAR-T programs on the same day, forcing the field to reckon with safety challenges that may be inherent to translating oncology science into autoimmune disease.

Policy

Teaching the Machine to Be a Doctor: What the FDA's GenAI Device Framework Really Means

The FDA's new discussion paper on generative AI-enabled medical devices proposes evaluating AI systems the way physicians are evaluated. The implications for medtech, digital health, and the future of clinical AI are significant.

Pharmaceuticals

The Triple-G Black Market: What Lilly's Retatrutide Lawsuits Reveal About the GLP-1 Era

Eli Lilly filed six lawsuits against black-market sellers of retatrutide on August 12, 2026. The legal action reveals a deeper structural tension in the obesity drug market that litigation alone cannot resolve.